Company intelligence / Profile preview
Rise Therapeutics
Rockville, Maryland, United Statesrisetherapeutics.com ↗
- Ownership
- Private
- Employees
- ~15
- Development stage
- Phase 1
01
Overview
Currently has four products in Phase 1 clinical trials. R-3750 and R-2487 have completed dose escalation enrollment stages and are moving to dose expansion stages. R-3750 is being tested for ulcerative colitis, and R-2487 for rheumatoid arthritis. Both have shown safety profiles that allow progression to expansion enrollment.
- Therapeutic areas
- GastroenterologyImmunologyEndocrinologyOncologyInfectious Diseases
- Modalities
- Oral Immune BioModulatorsbiologicslive biotherapeutic productsimmunological-based biologicscellular-based immune therapies
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)National Institute of Health (NIH)
Beyond the preview
Go deeper on Rise Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rise Therapeutics.